Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Treasury Shares (2020 - 2025)

Protalix BioTherapeutics (PLX) has 9 years of Treasury Shares data on record, last reported at $862816.0 in Q4 2024.

  • For Q4 2024, Treasury Shares fell 26.49% year-over-year to $862816.0; the TTM value through Dec 2024 reached $862816.0, down 26.49%, while the annual FY2024 figure was $862816.0, 26.49% down from the prior year.
  • Treasury Shares reached $862816.0 in Q4 2024 per PLX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.2 million in Q4 2023 and bottomed at $291474.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $682113.4, with a median of $624580.0 recorded in 2020.
  • Peak YoY movement for Treasury Shares: plummeted 36.36% in 2022, then surged 302.67% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $624580.0 in 2020, then decreased by 26.67% to $458027.0 in 2021, then tumbled by 36.36% to $291474.0 in 2022, then soared by 302.67% to $1.2 million in 2023, then fell by 26.49% to $862816.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $862816.0 in Q4 2024, $1.2 million in Q4 2023, and $291474.0 in Q4 2022.